Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL)

被引：0
|
作者：
Younes, A. [5 ]
Kuruvilla, J. [4 ]
Pro, B. [5 ]
Wedgwood, A. [5 ]
Li, Z. [3 ]
Drouin, M. [3 ]
Patterson, T. [3 ]
Ward, R. [2 ]
Martell, R. E. [3 ]
Bociek, R. G. [1 ]
机构：
[1] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA
[2] Pharm Corp, Clin Operat, Boulder, CO USA
[3] Drug Dev MethylGene Inc, Montreal, PQ, Canada
[4] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada
[5] Univ Texas Houston, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [21] Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).
    Garcia-Manero, Guillermo
    Yang, Allen S.
    Giles, Francis
    Faderl, Stefan
    Ravandi, Farhad
    Cortes, Jorge
    Newsome, Willie M.
    Issa, Jean-Pierre
    Patterson, Tracy-Ann
    Dubay, Marja
    Li, Zuomei
    Kantarjian, Hagop
    Martell, Robert E.
    BLOOD, 2006, 108 (11) : 552A - 553A
  • [22] Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)
    Garcia-Manero, G.
    Yang, A. S.
    Klimek, V.
    Luger, S.
    Newsome, W. M.
    Berman, N.
    Patterson, T.
    Maroun, C.
    Li, Z.
    Ward, R.
    Martell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL).
    Carlo-Stella, Carmelo
    Guidetti, Anna
    Viviani, Simonetta
    Bonfante, Valeria
    Valagussa, Pinuccia
    Marchiano, Alfonso
    Crippa, Flavio
    Zambelli, Stefania
    Fasola, Cinzia
    Corradini, Paolo
    Tarella, Corrado
    Di Nicola, Massimo
    Gianni, Alessandro M.
    BLOOD, 2008, 112 (11) : 896 - 897
  • [24] Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML)
    DiPersio, John
    Stadtmauer, Edward A.
    Nademanee, Auaypom P.
    Stiff, Patrick
    Micallef, Ivana
    Angell, J.
    Bridger, G.
    Calandra, Gary
    BLOOD, 2007, 110 (11) : 137A - 137A
  • [25] A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)
    Christian, Beth
    Kopko, Anne
    Fehniger, Todd A.
    Bartlett, Nancy L.
    Blum, Kristie A.
    BLOOD, 2012, 120 (21)
  • [26] MGCD0103, an oral isotype-selective HDAC inhibitor, has antitumor activity via the induction of the expression of Annexin A1 on AML1/ETO AML in vitro and in vivo
    Nameki, Daisuke
    Masuko, Norio
    Fujita, Ryouto
    Sugiura, Shin
    Yamamoto, Yasuji
    Minamiguchi, Kazuhisa
    Matsuo, Ken-Ichi
    CANCER RESEARCH, 2011, 71
  • [27] Oral panobinostat (LBH589), a novel deacetylase inhibitor (DACI), demonstrates clinical activity in relapsed/refractory Hodgkin lymphoma (HL)
    Spencer, A.
    DeAngelo, D. J.
    Prince, H. M.
    Bhalla, K. N.
    Fischer, T.
    Liu, A.
    Parker, K.
    Jalaluddin, M.
    Scott, J. W.
    Ottmann, O. G.
    ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [28] A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)
    Christian, Beth
    Wei, Lai
    Sexton, Jennifer
    Jaglowski, Samantha M.
    Devine, Steven M.
    Fehniger, Todd A.
    Wagner-Johnston, Nina
    Bartlett, Nancy L.
    Blum, Kristie A.
    BLOOD, 2014, 124 (21)
  • [29] Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors
    Siu, L. L.
    Carducci, M.
    Chen, E. X.
    Maclean, M.
    Pili, R.
    King, S.
    Patterson, T.
    Li, Z.
    Kalita, A.
    Reid, G. K.
    EJC SUPPLEMENTS, 2006, 4 (12): : 94 - 95
  • [30] The Histone Deacetylase Inhibitor MGCD0103 Down Regulates CD30, Activates NF-Kb, and Synergizes with Proteasome Inhibitors by HDAC6 Independent Mechanism in Hodgkin Lymphoma.
    Buglio, Daniela
    Mamidipudi, Vidya
    Khaskhely, Noor M.
    Gloghini, Annunziata
    Carbone, Antonino
    Heise, Carla
    Besterman, Jeffrey M.
    Martell, Robert E.
    MacBeth, Kyle J.
    Younes, Anas
    BLOOD, 2009, 114 (22) : 1438 - 1438
12345